![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switch to Stribild vs Continuation of NVP or RPV with FTC and TDF in Virologically Suppressed HIV Adults:
A STRATEGY-NNRTI Subgroup Analysis
|
|
|
Reported by Jules Levin
HIV Drug Therapy
November 2-6, 2014
Glasgow, UK
H Stellbrink1, A Antinori2, A Pozniak3, J Flamm4, F Bredeek5, K Patel6, W Garner6, and D Piontkowsky6
1ICH Study Center, Hamburg, Germany; 2Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Italy;
3St Stephens Centre, Chelsea and Westminster Hospital, London, UK; 4Kaiser Permanente, Sacramento, CA, USA;
5Metropolis Medical Group, San Francisco, CA, USA; 6Gilead Sciences, Inc., Foster City, CA, USA
![Glascow1.gif](../images/110714/110714-2/Glascow1.gif)
![Glascow2.gif](../images/110714/110714-2/Glascow2.gif)
![Glascow3.gif](../images/110714/110714-2/Glascow3.gif)
![Glascow4.gif](../images/110714/110714-2/Glascow4.gif)
![Glascow5.gif](../images/110714/110714-2/Glascow5.gif)
![Glascow6.gif](../images/110714/110714-2/Glascow6.gif)
![Glascow7.gif](../images/110714/110714-2/Glascow7.gif)
![Glascow8.gif](../images/110714/110714-2/Glascow8.gif)
![Glascow9.gif](../images/110714/110714-2/Glascow9.gif)
![Glascow10.gif](../images/110714/110714-2/Glascow10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|